9 April 2025

Ref: DOIA-REQ-0011153-Maria Lucento

Maria Lucento
Email: [FYI request #30415 email]

Tēnā koe Maria Lucento,

Thank you for your email of 13 March 2025 to the Ministry of Business, Innovafion and Employment
(MBIE) requesfing, under the Oﬃcial Informafion Act 1982 (the Act), the fol owing informafion:

I request any documents MBIE may have about Genomics Aotearoa and infrastructure (as it is
commonly deﬁned) in the new contract.

Background

“Infrastructure as it is commonly deﬁned”

As context for your quesfion, on 5 November 2024 you requested MBIE to provide documents on
“infrastructure built with funding provided by MBIE to Genomics Aotearoa that meets either the
Infrastructure Commission's or the Treasury's descripfion of infrastructure”.

MBIE responded on 3 December 2024 to your earlier response, nofing that funding for Genomics
Aotearoa:
  did not fund infrastructure as defined by the Treasury and The New Zealand Infrastructure
Commission Te Waihanga
  funded infrastructure in line with the SSIF Infrastructure definition in the Strategic Science
Investment Fund Investment Plan 2017-2024 (Strategic Science Investment Fund: Investment
Plan 2017 - 2024)
  allowed Genomics Aotearoa to access computing infrastructure through a partnership with the
National e-Science Infrastructure platform, which is funded through SSIF Infrastructure.

Further to our response of 3 December, we note that the Strategic Science Investment Fund Investment
Plan 2017-2024 included the fol owing descripfion of government’s intenfion for the Advanced Genomics
Research Plafform (p23):

“The Government is invesfing in a new cross-insfitufional research plafform that wil  produce high
quality research capability for the whole science sector. The Call for Proposals for this investment
is now closed and the provider wil  be announced in 2017. The new plafform wil  grow excel ent
genomics research capabilifies in New Zealand by building on and growing links to other world-
leading genomics research centres around the world, maintaining eﬀecfive relafionships with New
Zealand’s genomics scienfists and stakeholders, and by generafing world-leading excel ent
research on genomics. New Zealand has signiﬁcant capability in bioinformafics and the
interpretafion of genomic informafion; we expect this capability to be leveraged into valuable
outcomes including internafional col aborafions.”
1

Your current request references “infrastructure as it is commonly deﬁned.” We interpret “commonly
deﬁned” to the items named in the deﬁnifions you referenced in your request of 5 November 2024,or
similar deﬁnifions – for instance (using the deﬁnifion from The New Zealand Infrastructure Commission Te
Waihanga) “’horizontal’ physical networks (principally transport, water and energy and
telecommunicafions); and ‘verfical’ infrastructure (buildings such as hospitals, schools and prisons)”. An
ordinary person (who is unlikely to be familiar with the SSIF Investment Plan) is likely to consider physical
items such as supercomputers or very high-speed internet connecfions as infrastructure. We consider it
less likely that such a person would consider the capability, excel ence research and col aborafions
referenced in the SSIF Investment Plan as infrastructure.

“In the new contract”

In December 2024, MBIE contracted the University of Otago to confinue delivering the Advanced
Genomics Research Plafform for a further 5.5 years, from 1 January 2025 to 30 June 2030.

The reinvestment fol owed decisions made by the Hon Judith Col ins as Minister of Science, Innovafion
and Technology. Documents relevant to that decision are available in the Minister’s response to an Oﬃcial
Informafion Act request by Erin Cordiﬀ at Science System Advisory Group Nafional Research Priorifies - a
Oﬃcial Informafion Act request to Judith Col ins - FYI.
The reinvestment:
  maintains the goals of the Advanced Genomics Research Platform from the previous contract
  seeks a stronger focus on the fol owing areas in the renewed Platform:
o  enabling genomic research which has the potential to deliver economic benefits to New
Zealand
o  research and capability development delivering on the Government’s priorities for
biotechnology
o  a strategy-led approach to research prioritisation to ensure the entirety of the Platform is
delivering on the priorities above.

The goals of the Plafform are to:
  establish an agile, leading-edge col aborafive plafform of research on genomics that establishes
new connecfions in the New Zealand genomics sector and with genomics research end-users
  grow genomics capability in New Zealand through excellent genomics research
  grow new science col aborafions with genomics research centres, networks and teams that are
doing world-leading work and
  increase the adopfion and impact of genomics technology for scienfists, relevant end-users and
their sectors.

Note that the goals and areas of stronger focus do not include an explicit requirement for the Plafform to
build infrastructure as it is commonly deﬁned.

Documents relevant to your speciﬁc request
Please ﬁnd aftached the documentafion relevant to your request.

A public statement from the new contract for the Advanced Genomics Research Plafform is available at
Advanced genomics research plafform | Ministry of Business, Innovafion & Employment (under the
heading “Read an extract from the public statement 2025-2030 that supports the further investment”).
The public statement notes that the Plafform wil  begin a transifional period from January 2025,
maintaining key capability and preparing for a new work programme which will be in place "by the second
half of 2025".
2

MBIE has provided the University of Otago with a document so that they could prepare a Work
Programme, updated Outcome Logic and Key Performance Indicators for the period 1 January 2025 to 30
June 2030. This document, enfitled Guide to Preparing your Work Programme, is aftached as Annex 1.
The Guide does not include a requirement the Plafform to build infrastructure in the sense in which it is
commonly deﬁned. However, it notes that, in order the achieve the goal of “Increasing the adopfion and
impact of genomics technology for scienfists, relevant end-users and their sectors”, the Plafform wil
“Generate improved access to high-quality genomics research and infrastructure” (page 6). It also notes
that MBIE expects that "equipment and assets [in the Plafform] wil  be purchased and owned by relevant
insfitufions" (page 6).

MBIE has received versions of the Work Programme, and these are under assessment. These documents
have been withheld under the fol owing secfions of the Act:

  9(2)(ba)(i), to protect information which is subject to an obligation of confidence or which any
person has been or could be compelled to provide under the authority of any enactment, where
the making available of the information would be likely to prejudice the supply of similar
information, or information from the same source, and it is in the public interest that such
information should continue to be supplied;
  9(2)(j), to enable a Minister of the Crown or any public service agency or organisation holding the
information to carry on, without prejudice or disadvantage, negotiations (including commercial
and industrial negotiations).

I do not consider that the withholding of this informafion is outweighed by public interest considerafions
in making the informafion available.

If you wish to discuss any aspect of your request or this response, or if you require any further assistance,
please contact me at [email address].

You have the right to seek an invesfigafion and review by the Ombudsman of this decision. Informafion
about how to make a complaint is available at www.ombudsman.parliament.nz or freephone 0800 802
602.

Nāku noa, nā

Trevor Drage
Manager Strategic Investments
Science System Investment and Performance

3

Annex 1: Guide to Preparing your Revised Work Programme: Advanced Genomics Research Plafform,
March 2025

Guide to Preparing your Revised Work
Programme:
Advanced Genomics Research Platform

March 2025

4

link to page 17 link to page 17
Guide to Preparing Your Revised Work
Programme for the Advanced Genomics
Research Platform
Use this template to complete your revised Work Programme, draft outcome logic and draft Key
Performance Indicators for the Strategic Science Investment Fund Advanced Genomics Research Platform
(the Platform). This is a deliverable for contract UOO2462 Advanced Genomics Research Infrastructure
Platform: Genomics Aotearoa.

A Work Programme is a planning document that outlines how you intend to achieve your objective and
includes the structures, processes, and resources to support you doing this (how, what, when and who).
The Work Programme should cover the period 1 January 2025 to 30 June 2030, and have a stronger focus
on biotechnology and commercial impact of research than the original Platform Plan in contract
UOOX1702 Genomics Aotearoa, a national platform for genomics and bioinformatics.

The Outcome Logic Framework will be a tool used by the Board and Platform leadership to actively guide
decision making.  You are encouraged to update the existing Outcome Logic Framework in contract
UOOX1702, to reflect the stronger focus on biotechnology and commercial impact of research within
your revised work programme.

You should update the Key Performance Indicators (KPIs) in UOOX1702, to reflect the revised timeframe
and focus as above.

The Work Programme, Outcome Logic Framework and KPIs will form the basis of a revised Platform Plan
(Schedule 2) in the contract UOO2462 between MBIE and the University of Otago should they be deemed
satisfactory.  Note that MBIE may seek further changes to the submitted documents prior to finalisation.

By submitting your revised Work Programme, you are agreeing to Appendix One: MBIE’s funding policies,
terms and conditions.
Revised Work Programme Completion and Submission Requirements
Use this template to complete your revised Work Programme in MS WORD.
Respond to all questions and use sub-headings if appropriate to improve readability.
Use pictures, graphs, and hyperlinks sparingly.
Email your revised Work Programme, updated Outcome Logic Framework, and renewed Key Performance
Indicators to [email address] by 31 March 2025.
Timeline
These are the key tasks and dates for the Platform revisions, assessment, and contracting.

Date
Key Activity
31 March 2025
Submit revised Work Programme, updated Outcome Logic Framework, and
renewed KPIs to MBIE
6

April-May 2025
Assessment Panel meets – Platform representatives may be invited to join
part of the meeting to answer Panellists’ questions
Early June 2025
MBIE provides feedback from assessment, which may include requests for
further revisions of Work Programme, Outcome Logic Framework and KPIs
Late June 2025
Revisions to Work Programme due (if required)
July 2025
Host notified of MBIE decision
August 2025
Contract variation will be initiated to integrate the Work Programme
By no later than 30  Host submits updated Consortium Agreement and IP Management Plan to be
September 2025
included into contract variation process
All dates are NZ Standard Time. Final submission and assessment dates are dependent on the Platform
Host’s progress in revising the Work Programme and Assessment Panel member availability. If these
dates change, we will let you know by email.
How Your Work Programme Will be Assessed
Your Work Programme will be assessed and scored by an Assessment Panel using the Assessment Criteria
below, as either:
Excellent
Good but some gaps
Insufficient

We will let you know who is on the Panel before the assessment starts. We may seek external advice in
this assessment. After the Work Programme is assessed, we will provide feedback. We may recommend
changes and ask you to submit a revised version.
Assessment Criteria
The extent to which the Platform contributes to the Platform’s objective.
The extent to which the Platform will meet the investment signals and investment goals, and deliver
against SSIF performance areas:
 Strategic intent, including:
○  Establishing an agile, leading-edge collaborative platform of research on genomics that
establishes new connections in the New Zealand genomics sector and with genomics
research end-users
○  How the Platform will take a strategy-led approach to research prioritisation to ensure
the entirety of the Platform is delivering on creating economic benefits, and
biotechnology capability
 Impact, including:
○  Enabling genomic research that has the potential to deliver economic benefits to New
Zealand
○  Increasing the adoption and impact of genomics technology for scientists, relevant
end-users and their sectors.

7

 Science excellence
 Horizons and co-funding/leverage
 Investing in people, including:
○  Growing genomics capability in New Zealand through excel ent genomics research
○  Research and capability development delivering on the Government’s priorities for
biotechnology.
 Vision Mātauranga
 Domestic and international collaboration, including:
○  Growing new science collaborations with genomics research centres, networks and
teams that are doing world-leading work.
The extent to which the Platform’s operational structure and resourcing provides confidence that it will
enable appropriate and timely decision-making processes, and support the implementation and
management of the Platform.
The extent to which intellectual property, risk management and open research is outlined appropriately.
The robustness and transparency of the process to develop the revised Work Programme.

The Outcome Logic Framework is also assessed against the criteria.

KPIs are not assessed against the criteria; the Assessment Panel may provide feedback on KPIs to inform
contract negotiations.
Decision Making Process
MBIE’s General Manager, Science System Investment and Performance will make the final decision on the
revised Work Programme, Outcome Logic Framework, and KPIs based on recommendations from the
Assessment Panel Chair. This decision may include contract conditions.
About the Advanced Genomics Research Platform
Purpose of the Platform
In 2017, the then Minister of Science and Innovation approved the purpose of the Advanced Genomics
Research Platform, the science priorities the Platform will address, and the way the research is to be
undertaken.

In September 2024, the Minister of Science, Innovation and Technology confirmed support for continued
investment on the condition that the renewed investment be more aligned to current government
priorities, particularly in the advancement of biotechnology and commercialisation of science.

While the overal  goals for the Advanced Genomics Research platform remain unchanged, the Minister
has agreed to a stronger focus on the following areas in the renewed Platform:

•
Enabling genomic research that has the potential to deliver economic benefits to New Zealand.
•
Research and capability development delivering on the Government’s priorities for
biotechnology.
•
A strategy-led approach to research prioritisation to ensure the entirety of the Platform is
delivering on the priorities above.

8

Investment Goals

Establish an agile, leading-edge col aborative platform of research on genomics that establishes new
connections in the New Zealand genomics sector and with genomics research end-users

  Generate excellent, high impact, world-leading research on genomics.
  Develop relationships with end-users and establish paths to impact for genomics research.
  Leverage research outcomes to achieve economic, health, social and environmental impacts.
Grow genomics capability in New Zealand through excellent genomics research
  Generate an increased base of genomics capability, including attracting and training new
researchers.
  Develop partnerships that support access to research infrastructure, knowledge and skills to
support New Zealand’s genomics priorities.
  Leverage New Zealand expertise and scientific strengths to raise the performance and
international standing of New Zealand genomics.
Grow new science col aborations with genomics research centres, networks and teams that are doing
world-leading work.
  Generate new connections and partnerships with leading domestic and international partners.
  Develop connections that complement and enhance New Zealand capabilities.
  Leverage connections to generate impact from research and create commercial opportunities for
New Zealand genomics.

Increase the adoption and impact of genomics technology for scientists, relevant end-users and their
sectors. [Impact/Col aboration/Excellence]
  Generate improved access to high-quality genomics research and infrastructure.
  Develop investment, procurement and partnership models to boost uptake of genomics
technology amongst researchers and end-users.
  Leverage genomics technologies for greater economic, social and environmental impacts.
What is Fundable
Costs directly related to the science programme, and for connecting with industry, end-users, and
communities for impact.
What is Not Fundable
Infrastructure and science that is already funded through other New Zealand funding mechanisms or
agencies.
A large part of the science portfolio sourced and funded through contestable processes.
A network that only acts as contracts for service or as a Platform for hire.
Projects that don’t develop science capability and scientists’ ability to interact with key stakeholders.
Discrete, unconnected projects.
Costs not directly related to the science programme.
Science services (repeatable, codified process or R&D diffusion), and other steps in translation where
industry or key end-users could fund the activity.

We expect that equipment and assets will be purchased and owned by relevant institutions.

9

Advanced Genomics Research Platform – Work
Programme Template
Hosted by University of Otago
Section 1: Contact Information
1.1  Primary Contact
Provide the name, email address and telephone number of the primary contact person for the
Plan. This contact must have the authority to discuss the work programme with us.

Enter your answer here...

1.2  Secondary Contact
Provide a name, email address and telephone number of a second contact person. This secondary
contact must differ from the primary.

Enter your answer here...

Section 2: Summary Information
2.1  Executive Summary:
In 300 words or less provide an executive summary of the vision for a world class Advanced
Genomics Platform in 2030.

Enter your answer here...

2.2  Public Statement:
In 500 words or less provide a short summary of the Platform for public release (do not include
any confidential information). Include:
what the Platform is planning to do (including anticipated impact)
why it is being done
when it will be done
by whom.
Also include:
  web links to additional information, for example, links to the website for the Platform
  the name, logo (optional), and web address of the Platform host
  the name (optional), phone number and/or email address of a contact who can provide
more information.

Enter your answer here...

Section 3: The Platform
In 3,500 words or less, provide a narrative for each of the following SSIF investment signals:
Strategic intent, including:
10

○  Establishing an agile, leading-edge collaborative platform of research on
genomics that establishes new connections in the New Zealand genomics sector
and with genomics research end-users
○  How you will take a strategy-led approach to research prioritisation to ensure
the entirety of the Platform is delivering on creating economic benefits, and
biotechnology capability
Impact, including:
○  Enabling genomic research that has the potential to deliver economic benefits to
New Zealand
○  Increasing the adoption and impact of genomics technology for scientists,
relevant end-users and their sectors.
Science excellence
Horizons and co-funding/leverage
Investing in people, including:
○  Growing genomics capability in New Zealand through excellent genomics
research
○  Research and capability development delivering on the Government’s priorities
for biotechnology.
Vision Mātauranga
Domestic and international collaboration, including:
○  Growing new science collaborations with genomics research centres, networks
and teams that are doing world-leading work.

When writing this section, your narrative should include:
your vision for a successful Platform in 2030, and your strategy to achieve that vision
how the Platform’s science, capabilities, connections, and infrastructure will enable the
Platform to achieve this vision
how capability and research outcomes generated during the 2017-2024 funding of the
Advanced Genomics Research Platform will be built on in the 2025-2030 phase of the
Platform
any areas (if any) not carried forward
the opportunities to achieve increased impact, particularly in the advancement of
biotechnology and commercialisation of science
how the Platform will adapt if priorities change.

Enter your answer here...

11

Section 4: Work Programme Details
4.1  Science programme
In 2000 words or less outline the proposed work to be carried out over the term of the Platform.
Include:
which projects are underway, which programmes are ready to start, and which require further
development (include the process and timeframe for further development)
key delivery aspects expected within the Platform and how these feed into the broader work
programme and updated Outcome Logic Framework
how you will bring new methodologies, technologies, commercialisation, or people into the
Platform, and
how each programme integrates with the rest of the Platform.

You may want to structure your programme around major themes or areas. Include:
a descriptive programme title
a detailed description of the science or process to design the science programme, impacts and
process to achieve impacts
key personnel and collaborating partners
the start and end dates
indicative budget
how the work programme will adapt or pivot in a strategic or responsive sense to internal and
external drivers over time.

Enter your answer here...

4.2  Science, network, and implementation partners
We expect the team and network to include relevant capability from a range of research and
implementation partners. In 1000 words or less, outline for each partner organisation:
the name of the partner organisation
the expertise or science infrastructure they bring to, or the role that they will fill, in the
programme
how they will help the programme achieve impact
the status of the relationship with Host.
Outline the processes you will use to determine funding flows to research partners.

Outline the process you are using to refresh the existing Consortium Agreement.

Enter your answer here...

4.3  Development of the revised Work Programme
In 500 words or less outline:
the processes used to develop the revised Work Programme, including co-development and
consultation.
the stakeholders and partners that you have consulted
how their feedback has been integrated
changes that have been made to the revised Work Programme due to their feedback
how you have drawn on the expertise of the existing Platform advisory bodies, the Platform
Governance Board, the International Advisory Panel and the Science Leadership Team in
12

the development of the revised Work Programme.

Enter your answer here...

4.4  Indicative Budget (by expense category)
Funding is up to $5 million (excluding GST) per year over five and a half years. Provide an
indicative budget for your Platform using the following headings:
Projects/Programmes
○  Personnel cost
○  Direct project costs (eg materials, consumables, travel)
○  Overheads
○  Subcontracting
○  Co-funding (if applicable)
Platform leadership and operations
Please include any rationale or assumptions underlying the proposed figures, and if you expect
changes over time.

Total income must equal expenditure (over the life of the full Platform phase) and all values
should exclude GST. Please include any rationale or assumptions underlying the proposed figures.
Enter your indicative annual budget here (amend figures as necessary).

What is not fundable:
We expect that equipment and assets will be purchased and owned by relevant institutions.

4.5  Key Performance Indicators
Provide indicative Key Performance Indicators (KPIs) (at least one per performance area below)
that show how you will measure your programme’s performance over the term of the investment.

We recommend that you take the most recent KPIs from the contract UOOX1702 Genomics
Aotearoa, a national platform for genomics and bioinformatics and update them to reflect the
outcome logic framework and work programme focus on harnessing biotechnology for economic
and commercial impact.

KPIs should:
illustrate performance that reflects the Government’s investment goals and the expected
benefits of the investment
be SMART (specific, measurable, achievable (even if aspirational) relevant and time bound)
show how the outputs of your Platform will lead to delivery of impact through excellent science
and building capability
be measures that can track progress over time.
The panel will provide feedback on the KPIs, and we will work with you to negotiate final KPIs to
be incorporated into the contract. For further information see the SSIF Performance Framework.

Use the table below to complete and format your response.
Performance Area*
Measure
Target
Due Date
13

Strategic Intent (Strategic

Intent)
Impact (Impact)

Science Excellence

(Excellence)
Horizons and co-

funding/leverage (Research
Horizons)
Investing in People (Capability

Development)
Vision Mātauranga (Vision

Mātauranga)
Domestic and International

Collaboration (Collaboration
and Partnerships)
* Bracketed titles indicate how Performance Area wil  appear in Pītau.

Section 5: Programme Governance, Leadership, and management
5.1  Governance and advisory bodies
In 500 words or less, outline how the Platform will be governed, including the structure and
processes in place to ensure fair and transparent prioritisation and allocation of funding to a range
of science providers.
  Name and provide the purpose of the current advisory groups to the Platform.
  Outline any changes you propose to these groups, and the rationale for these changes.

Enter your answer here...

5.2  Science Leadership
Provide details of the key personnel who will be involved in the Platform and provide supporting
CVs. Only include key personnel who are confirmed at the time you submit the Work Programme.

Key personnel
*Science Leader(s): the researcher(s) responsible for leading science/research and their FTE
commitment; typically, this is the Platform Director/Co-Directors.
*Key Researcher(s): other team members involved in the leadership of the Platform, whose
expertise is critical to the success of your research. They may be from a contracted
organisation, a subcontracted agency, or a stakeholder who is providing cash or in-kind co-
funding of the research. At least one key researcher must be named. Only include key
researchers who are confirmed at the time you submit your Work Programme; we
understand that key researchers for programmes may not be known at the time you submit
the Platform Plan.
*Key Individual(s): team members involved in the leadership of the Platform, the wider
network, or the implementation who are not researchers but whose contribution is critical
to the success of the Platform.
CVs should conform to the RS&T or Narrative CV format. You should email these CVs to
[email address] at the time you submit the proposal.
14

Diversity data
As part of MBIE’s diversity policy, we collect diversity data on researchers. As the detailed makeup
of the team will not be known when you submit your Work Programme, we will not collect data at
this stage. We will collect this data through reporting and other means such as surveys. We will
advise the host of the means used to collect this data during the contracting process for the
Platform.

For more information on the collection of diversity information, see our webpage Diversity in
science.

Note that MBIE will not fund individuals employed by local or central government but may fund
costs associated with their involvement other than salary.
Use the table below to complete and format your response…
Role
Ful  Name
CV
FTE
Email Address
*Science leader
Mandatory
Mandatory
Mandatory
Mandatory
*Key researcher
Mandatory
Mandatory
Mandatory
Mandatory
*Key individual
Mandatory
Optional
Not Required
Mandatory

Section 6: Sensitive Technologies / Dual Use
6.1  Technologies of Special Interest
Identify any technologies of special interest relevant to the Programme. Complete all questions. If
you select ‘yes’, please provide details of how and in what context the technology will be used.
Does the science involve use of:
Gene technologies?   Yes/No
Live animal testing?   Yes/No
Developing algorithms which predict human behaviour or automate decision-making impacting
humans for example, Artificial Intelligence?   Yes/No
Human data mining?   Yes/No
Industrial fermentation?   Yes/No
Nanotechnology?  Yes/No
Xenotransplantation?   Yes/No
Technologies that could have military or security application?   Yes/No

Section 7: Additional Information
7.1  Intellectual Property Management
In 1000 words or less outline:
how you will identify, protect, and share any intellectual property generated through the
delivery of the Platform to ensure maximum benefit to New Zealand. This includes
management of intellectual property, including provisions for making data public and
principles for covering any exclusions, including any mātauranga Māori, between
collaborators and contract partners, including MBIE.
15

if the success of your programme is dependent on access to existing intellectual property,
outline the agreements you have in place to use it and how you are taking a strategic
approach to accessing intel ectual property.

Enter your answer here...

7.2  Open research
In 250 words or less outline how the Platform will comply with the New Zealand Open Research
Policy

Enter your answer here...

7.3  Risk Management Plan
In 500 words or less outline your risk management plan, including:
Data management
Technology
Key personnel
Identification of duplication of science – internationally and domestically.
Cross reference other sections of the Platform if and where relevant.

Enter your answer here...

7.4  Other Information
In 500 words or less, if there are areas of the Work Programme that you are aware will require
further development, outline what these are and when these will be done by.

Enter your answer here...

7.5  Conflicts of interest
Declare any potential conflict of interest and say why there is a conflict. This may include possible
conflicts with assessors, a part of MBIE, or both. We will advise you of the Assessment Panel
members by email before the submission date.
Declare any conflicts here...

16

Appendix One: MBIE’s funding policies, terms and
conditions
By submitting your Work Programme, you are accepting and agreeing to MBIE’s funding policies, terms
and conditions. Neither this funding opportunity, nor any contract variation resulting from the invitation
process is intended to create a partnership agreement between MBIE and the University of Otago.
Funding policies
Our funding polices show our commitment to:
everyone having a fair and equal opportunity to participate in the science system to their fullest potential,
and
ensuring that all science data generated through its investments meets minimum expectations of good
data management and public availability.
For more see our web page Agencies, policies and budget initiatives.
Funding terms and conditions Relating to Submitting the Work Programme
By submitting your Work Programme you will be deemed to have agreed to the following:
MBIE may be required to release information supplied in your Plan in accordance with the Official
Information Act 1982 Act, or as otherwise required by law.
No contract or other legal obligations arise out of, or in relation to, development of Work Programmes
until we have a signed contract.
Intellectual property rights in your Plan are jointly owned by you and the Ministry of Business, Innovation
and Employment. By submitting your Work Programme you:
agree MBIE may use and disclose your Work Programme for any purpose, and
warrant that your Work Programme and its use by MBIE will not breach any third-party IP rights.
MBIE reserves the right to amend, suspend, cancel and/or re-issue these guidelines at any time.

Disclosure of information
MBIE may make public the following information:
The proposal title
The name of the Host (the Contracting organisation)
The names of all Partner organisations
The public statement (as provided in the proposal)
The total amount of funding provided
The contract start and end dates and contract status (if funded)
MBIE asks that you don’t release any media statement or other information relating to the process
outlined in this opportunity, or the submission or approval of any proposal to any public medium without
providing sufficient advance Notice to MBIE.

17

Document Outline

Guide to Preparing Your Revised Work Programme for the Advanced Genomics Research Platform